Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136696 | 1.00 | POLB (0.46) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2138231 | 0.88 | SYK (0.43) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2707664 | 0.88 | SYK (0.43) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2140325 | 0.88 | POLB (0.44) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2141011 | 0.88 | POLB (0.44) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2138671 | 0.86 | SYK (0.46) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2137495 | 0.86 | SYK (0.46) | POLBMAPTXBP1NPSR1TDP1 | |
| SCHEMBL2139397 | 0.84 | SYK (0.42) | POLBSYKALDH1A1 | |
| SCHEMBL2139616 | 0.84 | SYK (0.42) | POLBSYKALDH1A1 | |
| SCHEMBL2708989 | 0.81 | POLB (0.48) | POLBSYKALDH1A1GAANTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447265-A1 | NOVEL THIOPHENE CARBOXAMIDE DERIVATIVE AND MEDICINAL USE OF SAME | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | POLB 4068/4885MAPT 4390/4885XBP1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.